ECLS for ARDS
The pathophysiology of respiratory dysfunction after major burns is multifactorial, and ARDS and inhalation injury are the most important factors.3,4,6 Burn-related ARDS may result from multiple risk factors, such as pneumonia, smoke inhalation, shock, bacteraemia, and blood product transfusion. The pro-inflammatory mediators not only initiate local tissue injury but also amplify the systemic inflammatory response. Eventually, dysregulation of inflammatory cytokines and leukotrienes leads to the breakdown of the pulmonary microvascular endothelial lining and the alveolar epithelial surface, which are together referred to as the alveolar-capillary barrier. The prevalence reported in mechanically ventilated patients after burn injury ranged from 32.6–53.2%, by Berlin definition,12 and 39.5% by American European Consensus Conference definition.5 It has been reported that the extent of full thickness burn predicts the development of severe ARDS, which is associated with greater duration of mechanical ventilation and higher mortality.13 Although ECLS has been documented as a crucial treatment for ARDS in some cohort studies,14 none of the randomized controlled trials could prove its efficacy on burn-related ARDS so far.
ECLS for inhalation injury
According to current published literature, extended burned TBSA, inhalation injury, and age are the best predictors of mortality in burn prognosis.7 Smoke inhalation injury can be divided into three different types of injury, including direct thermal injury to the upper airway, chemical irritation of the whole respiratory tract, and systemic toxicity owing to toxic gases.15 Each type of injury might cause systemic inflammatory response syndrome and has the potential to exacerbate into ARDS. To improve hypoxemia, the therapy for inhalation injury mainly includes mechanical ventilation and nebulized inhalation medication. However, once ARDS develops, the insufficient pulmonary oxygenation always results in sustained systemic hypoxemia and subsequent multiple organ dysfunction. Asmussen et al., reported a systematic review about ECLS in respiratory failure resulting from burn and smoke inhalation injury.9 They concluded that the level of evidence is limited due to insufficient patient numbers available in present literature. However, ECLS device and technology have improved and evolved over the last decades, thereby increasing the survival rate year by year. Similarly, further research on ECLS for smoke inhalation injury is warranted to prove its efficacy.
In our cohort, all patients had concomitant ARDS and inhalation injury. We thought that ARDS mainly resulted from large TBSA burned rather than inhalation injury. Although Liffner et al. reported that inhalation injury assessed by an inhalation lung injury score did not contribute to the development of ARDS,16 we believe that the inhalation injury is also a contributing factor for ARDS, which together exacerbated the respiratory dysfunction.
Literature review of ECLS for burn injury
Table 510,17−26 shows literature reviews from 1998 to present. There were eleven cohorts that supported the application of ECLS in burns with respiratory failure, which is mainly caused by ARDS, with PaO2/FiO2 below 100. The average TBSA ranged from 12–89%, and the average Baux score ranged from 55 to 149. The majority used VV-ECLS for systemic hypoxemia, while the minority used VA-ECLS for unstable hemodynamics, and cardiogenic and septic shock. The average survival rate ranged from 9.0–100%. There are only three cohorts enrolling more than 10 patients since 2016.21,24,26 For these three cohorts, each mean Baux score was 82.0, 64.2, and 64.0, with survival 9.0%, 45.4%, and 60%, respectively. Taking these three cohorts together for analysis, the overall mean Baux score was 68.7, and overall mean survival to discharge was only 42.8%. Our cohort had 14 patients enrolled, with a mean TBSA burned 81.6% and a mean Baux score of 120.3. Osler et al. claimed that inhalation injury would increase Baux score by 17 points, which was termed the revised Baux score.3 According to their scale formula, the predicted mortality of our cohort should be close to 90% with 137-point revised Baux score. Table 5 shows that the severity of our study is much more than that of all cohort studies. Inspiringly, our survival to discharge was 42.8%, which is not inferior to the aforementioned studies. This implies that with adequate rigorous patient selection, ECLS could be a salvage modality therapy for high-Baux patients.
Table 5
Literature review of ECLS applied for respiratory failure in severely burned adults
Study | Year | Number | Baux score (mean) | PaO2/FiO2 | PEEP (cmH2O) | Inhalation injury | ECLS Mode | Survival to discharge |
Patton et al.17 | 1998 | 1 | 55.4 | 81 | 17 | 100% | VV: 1 | 100% |
Chou et al.18 | 2001 | 3 | 90.7 | 46.1 | 15.7 | 66.6% | VV: 2 VV ◊ VA: 1 * | 66% |
Thompson et al.19 | 2005 | 2 | 67.5 | 62.5 | 21.5 | 100% | VV: 2 | 100% |
Soussi et al.21 | 2016 | 11 | 82.0 | 66 | 12 | 55% | VV: 8 VA: 2† VV + VA: 1 | 9.0% |
Kennedy et al.20 | 2017 | 2 | 78.5 | 43.5 | 16 | 0% | VV: 2 | 100% |
Hsu et al.10 | 2017 | 6 | 149.1 | 66.6 | 12.0 | 83% | VV: 2 VA: 4 ‡ | 16.7% |
Chiu et al.22 | 2018 | 5 | 104.7 | 87.1 | N/A | 100% | VV: 4 VA: 1 § | 60% |
Szentgyorgyi et al.23 | 2018 | 5 | 60.2 | 67.82 | 13.1 | 100% | VV: 5 | 80% |
Ainsworth et al.24 | 2018 | 11 | 64.2 | 82 | N/A | 27% | VV: 11 | 45.4% |
Dadras et al.25 | 2019 | 8 | 83.2 | 61.6 | 13.5 | 87.5% | VV: 7 VV ◊ VA: 1 ¶ | 62.5% |
Marcus et al.26 | 2019 | 20 | 64.0 | N/A | N/A | 10% | VV: 20 | 60% |
N/A, not available; VV, veno-venous; VA, veno-arterial; ARDS, acute respiratory distress syndrome; |
* One patient was transferred from VV to VA mode due to cardiogenic shock, but died of inferior vena cava (IVC) rupture. |
† VA mode was indicated due to unstable haemodynamic. One patient used combined VV and VA mode simultaneously. All three died of multiple organ failure. |
‡ VA mode was indicated due to unstable haemodynamic, and three died of multiple organ failure (MOF) and one died of cardiogenic shock. |
§ VA mode was indicated due to cardiogenic shock, but the patient died of infective endocarditis and subsequent septic shock. |
¶ One patient was transferred from VV to VA mode due to septic shock, and survived to discharge. |
Compare VV and VA survival and outcome
In our study, the survival rate of VV- and VA-ECLS were 50.0% (3/6) and 37.5% (6/8), respectively. The hazard ratio for mortality was 1.66 in VA-ECLS without significance. We had three survivors from VA-ECLS, and all these victims applied VA-ECLA on the basis of septic shock27, who did not respond to inotropes and vasopressors. However, on analyzing all patients of cohort studies in Table 5, the survival of VV- and VA-ECLS were 57.8% (37/64) and 10.0% (1/10), respectively. The hazard ratio was as high as 12.33 in VA-ECLS patients. In our preliminary experience, we observed that the most challenging issue in resuscitating burn shock patients was to maintain adequate intravascular volume.10 Compared to VV-ECLS, the pump flow of VA-ECLS was significantly lower in major burn injury despite excessive fluid administration and human albumin transfusion. The systemic inflammatory mediators and cytokines would disrupt the inter-endothelial junctional structure, affect vascular actomyosin contraction, and then change vascular permeability by increasing the outflow of macromolecules and fluid from vessels.28 This capillary leak syndrome would exacerbate in “large burn” patients,29 and would make burn shock patients vulnerable to hypovolemic and septic shock. According to past literature mentioned in Table 5, the majority of VA-ECLS were set for unstable hemodynamics and septic shock. It is noteworthy that hemodynamic instability before ECLS might imply a much more exacerbated capillary leak syndrome. As a result, the efficacy of VA-ECLS is limited in salvaging these patients from either hypovolemic or subsequent septic shock. Likewise, transfer from VV- to VA-ECLS should be applied with caution, despite reports available by Dadras that claim one survival after transfer to VA-ECLS.25
Limitations
There are several limitations in this study. First, the nature of this study is retrospective. The data and information were collected via medical records, which might have intrinsic bias. Second, the number of patients enrolled was too small. A very small proportion of burn patients require ECLS; hence, it is challenging to perform a prospective study. Third, these patients are extremely critical; hence, randomized trials cannot be performed due to ethical concerns. The patient cohort in our study yielded only 14 patients over an eight-year span, collected from a single burn center. Due to the rarity of ECLS applied in this scenario, multi-center observational or interventional studies would improve patient selection, ECLS indication, and consequent outcomes.
In conclusion, our study enrolled 14 patients. To the best of our knowledge, this
is the largest patient number so far. Our Baux score has been the highest. We demonstrate the benefits and efficacy of ECLS in major-burn patients with concomitant ARDS and inhalation injury through this study. With improvement and evolution of ECLS devices, including more biocompatible pumps and efficient oxygenators, and less thrombogenic tubes, these critical patients may benefit from ECLS in future. Further research with more cases is necessary to draw more solid evidence and robust conclusions.